https://peptidekey.com/news/fda-approves-foundayo-oral-glp1-orforglipron-lilly-2026 PeptideKey en 2026-04-03T07:00:00.000Z Lilly's Foundayo Approval Reshapes Oral GLP-1 Landscape https://peptidekey.com/news/fda-glp1-compounded-peptide-guidance-2026 PeptideKey en 2026-03-08T10:00:00.000Z FDA Issues New Draft Guidance on Compounded GLP-1 Peptides — What It Means for Research Suppliers https://peptidekey.com/news/obesity-drug-war-glp1-next-wave-novo-lilly-viking PeptideKey en 2026-03-06T09:00:00.000Z The Next Obesity Drug War: Beyond GLP-1 Discovery https://peptidekey.com/news/janoshik-coa-format-update-heavy-metals-2026 PeptideKey en 2026-03-10T09:00:00.000Z Janoshik Analytical Lab Expands COA Reporting — New Heavy Metal Screening Panel Now Standard https://peptidekey.com/news/ipamorelin-gh-pulse-sleep-research-2026 PeptideKey en 2026-03-26T15:50:58.498Z Ipamorelin's Sleep-Window GH Pulse Outperforms Older Secretagogues in Head-to-Head Data https://peptidekey.com/news/zealand-petrelintide-phase2-amylin-weight-loss-zero-nausea-2026 PeptideKey en 2026-03-31T03:00:00.000Z Zealand's Petrelintide Posts Phase 2 Data With Zero Vomiting — and That Changes Everything https://peptidekey.com/news/fda-14-peptides-ban-lifted-nyt-compounding-2026 PeptideKey en 2026-04-01T12:00:00.000Z The 14 Peptides FDA Is Unbanning: What Each One Actually Does https://peptidekey.com/news/oral-obesity-pill-race-foundayo-rybelsus-vk2735-aleniglipron-2026 PeptideKey en 2026-04-03T13:00:00.000Z The Oral Obesity Pill Race: A Four-Way Battle Reshaping Pharma https://peptidekey.com/news/peptide-sciences-shutdown PeptideKey en 2026-03-06T09:00:00.000Z Peptide Sciences: The Rise and Fall of the Research Peptide Market's Biggest Name https://peptidekey.com/news/rfk-fda-peptide-industry-hhs-enforcement-2026 PeptideKey en 2026-03-11T09:00:00.000Z RFK Jr.'s HHS and Makary's FDA: A Paradoxical Enforcement Era for Peptides https://peptidekey.com/news/bpc157-state-peptide-regulation-gray-zone-closing-2026 PeptideKey en 2026-03-21T16:00:00.000Z Three States Quietly Moved to Classify Research Peptides — The BPC-157 Gray Zone Is Closing https://peptidekey.com/news/china-tightens-peptide-export-controls-what-it-means-for-us-research-suppliers-i PeptideKey en 2026-03-14T01:09:03.535Z China Tightens Peptide Export Controls: What It Means for US Research Suppliers in 2026 https://peptidekey.com/news/fdas-q1-2026-enforcement-surge-warning-letters-hit-research-peptide-vendors-at-s PeptideKey en 2026-03-12T09:00:00.000Z FDA's Q1 2026 Enforcement Surge: Warning Letters Hit Research Peptide Vendors at Scale https://peptidekey.com/news/bachem-250m-us-expansion-glp1-manufacturing-2026 PeptideKey en 2026-03-16T20:33:06.659Z Bachem Is Spending $250 Million to Make Sure America Doesn't Run Out of Peptide Drugs https://peptidekey.com/news/peptide-sciences-closure-peptide-industry-shift PeptideKey en 2026-03-07T09:00:00.000Z Peptide Sciences Is Just the Beginning: Why the Research Peptide Market Is Shifting https://peptidekey.com/news/rfk-14-peptides-fda-reclassification-delay-five-weeks-2026 PeptideKey en 2026-04-03T16:00:00.000Z Five Weeks Later: RFK Jr.'s Peptide Promise Stalls at FDA, Leaving Industry in Limbo https://peptidekey.com/news/retatrutide-transcend-diabetes-phase3-triple-agonist-2026 PeptideKey en 2026-03-22T16:08:54.629Z Retatrutide Just Beat Every GLP-1 on the Market — In a Diabetes Trial Nobody Expected https://peptidekey.com/news/pinnacle-medicines-89m-series-b-oral-peptide-2026 PeptideKey en 2026-03-31T02:30:00.000Z Pinnacle Medicines Closes $89M to Crack the Oral Peptide Code https://peptidekey.com/news/mots-c-diabetes-pancreatic-senescence-2025 PeptideKey en 2026-03-16T14:00:00.000Z The Diabetes Paper Nobody Talked About https://peptidekey.com/news/glp1-compounding-loophole-closed-telehealth-semaglutide-2026 PeptideKey en 2026-03-22T16:08:56.870Z The GLP-1 Compounding Loophole Just Closed — And Telehealth Companies Are Pretending It Didn't https://peptidekey.com/news/lillys-oral-orforglipron-threatens-to-remap-peptide-industry-supply-chains PeptideKey en 2026-03-18T16:00:00.000Z Lilly's Oral Orforglipron Threatens to Remap Peptide Industry Supply Chains https://peptidekey.com/news/peptide-purity-verification-gap-third-party-testing-2026 PeptideKey en 2026-03-26T15:50:58.622Z Most Peptide Buyers Can't Verify What They're Getting — The Purity Gap Nobody Talks About https://peptidekey.com/news/epitalon-telomerase-institutional-longevity-research-2026 PeptideKey en 2026-03-26T15:50:58.668Z Epitalon Crosses From Underground to Institutional: Two University Labs Now Studying Telomerase Activation https://peptidekey.com/news/novo-nordisk-pauses-key-cagrisema-kidney-trial-amid-gi-safety-review PeptideKey en 2026-03-17T14:00:00.000Z Novo Nordisk Pauses Key Cagrisema Kidney Trial Amid GI Safety Review https://peptidekey.com/news/hims-novo-nordisk-partnership-glp1-compounding-resolved-2026 PeptideKey en 2026-04-03T10:00:00.000Z Hims & Hers Capitulates to Novo Nordisk, Signaling End of GLP-1 Compounding Gold Rush https://peptidekey.com/news/peptide-cartilage-repair-bpc157-tb500-science-desk PeptideKey en 2026-03-07T09:00:00.000Z The Cartilage Conundrum: Peptides Promise Regeneration, Clinical Proof Lags https://peptidekey.com/news/growth-hormone-peptide-market-boom PeptideKey en 2026-03-19T00:00:00.000Z The Growth Hormone Peptide Market Is Quietly Booming While GLP-1 Burns https://peptidekey.com/news/peptide-vendor-coa-fraud-hplc-fake-purity-testing-2026 PeptideKey en 2026-04-01T16:00:00.000Z 40% of Peptide Vendors Fail Quality Checks: Inside the COA Fraud Crisis https://peptidekey.com/news/roche-ct388-biased-agonist-no-plateau-obesity-phase2-2026 PeptideKey en 2026-04-01T15:00:00.000Z CT-388: The Obesity Drug That Never Plateaus — Roche's $2.7B Bet Pays Off https://peptidekey.com/news/viking-therapeutics-vk2735-glp1-gip-obesity-pipeline-vanquish PeptideKey en 2026-03-20T12:00:00.000Z Viking Therapeutics Bets $0 in Revenue Against Eli Lilly and Novo Nordisk — Inside the VK2735 Gamble https://peptidekey.com/news/cognitive-peptide-research-semax-selank-dihexa-2026 PeptideKey en 2026-03-25T16:02:00.400Z The Nootropic Peptide Underground Is Going Clinical — And Institutional Money Is Following https://peptidekey.com/news/huberman-gray-market-dead-compounding-pharmacies-2026 PeptideKey en 2026-03-23T17:02:56.605Z Huberman Declares the Gray Market Dead — Says Compounding Pharmacies Are 'Here to Stay' https://peptidekey.com/news/glp1-obesity-pipeline-2026-retatrutide-orforglipron-cagrisema PeptideKey en 2026-03-16T15:00:00.000Z Seven Readouts, Three Approvals, and a Monthly Shot: The 2026 Obesity Pipeline Is Absurd https://peptidekey.com/news/caqk-tetrapeptide-brain-injury-aivocode-phase1-2026 PeptideKey en 2026-03-23T18:27:22.007Z A Four-Amino-Acid Peptide Reversed Brain Damage in Pigs. Now Aivocode Wants to Try It in Humans. https://peptidekey.com/news/peptide-public-health-alarm-time-npr-teens-2026 PeptideKey en 2026-03-31T03:30:00.000Z TIME, NPR, and Public Health Groups All Sounded the Peptide Alarm in the Same Month https://peptidekey.com/news/oral-peptide-revolution-injectable-market-shift-2026 PeptideKey en 2026-03-24T15:33:48.254Z Oral Peptide Revolution Threatens Injectable Market, Reshaping Industry Supply Chains https://peptidekey.com/news/celebrity-peptide-culture-renner-silicon-valley-oscars-2026 PeptideKey en 2026-03-23T17:02:56.842Z From Renner's Snowplow to Silicon Valley's July 4th Parties: How Peptides Became America's Worst-Kept Secret https://peptidekey.com/news/humanin-motsc-nih-grant-mitochondrial-peptides-longevity PeptideKey en 2026-03-21T14:00:00.000Z Humanin & MOTS-c Just Got a $40M NIH Grant — Why Mitochondrial Peptides Are the New Longevity Frontier https://peptidekey.com/news/fda-wegovy-hd-semaglutide-7-2mg-approval-2026 PeptideKey en 2026-03-31T02:00:00.000Z FDA Approves Wegovy HD: Novo Nordisk's 7.2mg Semaglutide Raises the Dose Ceiling https://peptidekey.com/news/bpc-157-research-evidence-review-2026 PeptideKey en 2026-03-05T08:00:00.000Z What the Research Actually Says About BPC-157: A 2026 Evidence Review https://peptidekey.com/news/biohacker-md-how-peptides-went-from-bodybuilding-forums-to-longevity-clinics PeptideKey en 2026-03-14T13:18:10.257Z Biohacker, MD: How Peptides Went From Bodybuilding Forums to Longevity Clinics https://peptidekey.com/news/mots-c-mitochondrial-peptide-discovery-usc PeptideKey en 2026-03-04T09:00:00.000Z Mitochondria Speak: The Peptide MOTS-c Unveils a New Cellular Language https://peptidekey.com/news/hcg-regulatory-limbo-fertility-trt-biologics-2026 PeptideKey en 2026-03-24T15:33:48.720Z HCG's Regulatory Shift Creates Two-Tier Access for Fertility, TRT Patients https://peptidekey.com/news/chinese-api-supply-chain-tariff-pressure-2026 PeptideKey en 2026-03-03T07:00:00.000Z Inside the Supply Chain Collapse: How Chinese API Manufacturers Are Responding to U.S. Tariff Pressure https://peptidekey.com/news/fda-approves-icotyde-first-oral-peptide-il23-psoriasis PeptideKey en 2026-03-20T09:00:00.000Z FDA Approves ICOTYDE, the First Oral Peptide Drug to Block IL-23 — What It Means for the Industry https://peptidekey.com/news/glp1-compounding-crackdown-503b-patients-pharmacies-2026 PeptideKey en 2026-03-18T11:00:00.000Z GLP-1 Shortage's End Dismantles Compounding Market, Squeezing Patients and Pharmacies https://peptidekey.com/news/india-peptide-manufacturing-china-supply-chain-shift-2026 PeptideKey en 2026-03-24T15:33:48.855Z India Seizes Peptide Manufacturing Crown Amid China's Retreat https://peptidekey.com/news/eu-peptide-regulation-framework-ema-2026 PeptideKey en 2026-03-25T16:04:21.907Z Europe Moves First: The EU's Peptide Classification Framework Could Set the Global Standard https://peptidekey.com/news/rfk-peptide-reclassification-update PeptideKey en 2026-03-19T00:00:00.000Z Three Weeks After RFK Jr.'s Peptide Promise: What's Actually Happened https://peptidekey.com/news/cordenpharma-neuland-peptide-cdmo-billion-dollar-arms-race-2026 PeptideKey en 2026-04-01T14:00:00.000Z The $1.5 Billion Peptide Factory Arms Race: CordenPharma vs. Neuland https://peptidekey.com/news/peptide-cdmo-17-billion-manufacturing-race-bachem-cordenpharma-2026 PeptideKey en 2026-04-03T19:00:00.000Z Peptide CDMOs Chase GLP-1 Gold, But Oral Drugs Threaten Billions in SPPS Investment